ENTA · Enanta Pharmaceuticals Inc
United States · RS rating 19 · As of 2026-10-14
| Price | 11.18 USD |
|---|---|
| 1-day change | -3.0% |
| RS rating (overall / 1M / 3M / 12M) | 19 / 25 / 24 / 40 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 15 / 46 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +51.7% |
| Sales growth Q/Q | +23.1% |
| Distance from 52-week high | +33.6% |
| Market cap (USD) | $387.4M |